Effect of Soybean Peptide-Containing Beverage on Muscle Mass and Muscle Quality in Patients Admitted to Kaifukuki Rehabilitation Ward Historical control study

Effect of Soybean Peptide-Containing Beverage on Muscle Mass and Muscle Quality in Patients Admitted to Kaifukuki Rehabilitation Ward Historical control study - Effect of Soybean Peptide-Containing Beverage on Muscle Mass and Muscle Quality in Patients Admitted to Kaifukuki Rehabilitation Ward Historical control study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048802

Enrollment

Registered

2022-09-01

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebrovascular disease

Interventions

Control: Conventional inpatient diet (historical concoction) Beverages containing soy peptides 1 pack/day. At least 2 months according to the length of hospitalization. Casein-containing beverage 1 pa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with cerebrovascular disease who were admitted to the Recovery Rehabilitation Unit of Koyama Rehabilitation Hospital and who agreed to participate in the study

Exclusion criteria

Exclusion criteria: Patients whose general condition is not stable (deterioration of condition, possible transfer to other hospitals) Patients with soy allergy Patients with significant dysphagia (patients for whom ingestion of this product may induce aspiration pneumonia) Patients with low average nutritional intake (less than 80% of the energy requirement calculated by the Harris-Benedict formula) Patients who have difficulty consuming research products more than 3 days per week. Patients with significant edema Patients with severe renal or cardiac disease or diabetes mellitus (BNP > 200 pg/ml, eGFR < 30, HbA1c > 9.0%, any one of which is persistent) Patients who are judged to be inappropriate for the subject by the physician's judgment

Design outcomes

Primary

Measure	Time frame
Body composition (mainly skeletal muscle and body fat)	—

Secondary

Measure	Time frame
Assessment of Functional Activities of Daily Living, Dementia Independence for Daily Living, Functional Independence Measure (FIM), FIM gain, days in ward, total rehabilitation units, days in hospital after onset, MMSE, Revised version of the Ability for Basic Movement Scale II (ABMS II), grip strength, Borg Balance Scale, lower leg circumference, body weight, BMI, MUST, MNA-SF, GILM, average nutrient intake, protein requirement, average protein intake, energy per body weight, protein per body weight, NPC/N ratio, availability of nutritional supplements presence/absence, oral supplementation, non-protein calorie/nitrogen ratio calculation, sarcopenia diagnosis, blood tests	—

Measure

Time frame

Assessment of Functional Activities of Daily Living, Dementia Independence for Daily Living, Functional Independence Measure (FIM), FIM gain, days in ward, total rehabilitation units, days in hospital after onset, MMSE, Revised version of the Ability for Basic Movement Scale II (ABMS II), grip strength, Borg Balance Scale, lower leg circumference, body weight, BMI, MUST, MNA-SF, GILM, average nutrient intake, protein requirement, average protein intake, energy per body weight, protein per body weight, NPC/N ratio, availability of nutritional supplements presence/absence, oral supplementation, non-protein calorie/nitrogen ratio calculation, sarcopenia diagnosis, blood tests

—

Countries

Japan

Contacts

Public ContactEtsuko Kurata

Koyama Rehabilitation Hospital Department of Rehabilitation

eiyouka@momoha.or.jp0545-36-2000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026